After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever

When Genentech swooped in to buy NASH-focused Jecure Therapeutics back in 2018, a handful of the startup’s executives weren’t quite ready to disperse. The post After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever appeared first on 8five8 Therapeutics .